Market Newsdesk

SAN DIEGO, March 16, 2021 /PRNewswire/ — WD-40 Company (NASDAQ:WDFC) today announced that its board of directors declared on Tuesday, March 16, 2021 a quarterly dividend of $0.72 per share reflecting an increase of more than 7 percent compared to the previous quarter’s dividend.  The quarterly dividend is payable April 30, 2021 to stockholders of record at the close of business on April 16, 2021.

The Company also announced that it has scheduled its second fiscal quarter 2021 earnings conference call for Thursday, April 8, 2021 at 2:00 p.m. PDT.  On this call, management will discuss financial results, business developments and other matters affecting the Company. Other forward-looking or material information may also be discussed.

A live webcast of this event will be available on the Company’s investor relations website at http://investor.wd40company.com.  The webcast will be archived and available on the website for a one-year period following the conference call. 

The Company’s quarterly earnings press release will cross the wire after market close on April 8, 2021. Please visit the Company’s investor relations website to view the press release and other supporting materials.

About WD-40 Company
WD-40 Company is a global marketing organization dedicated to creating positive lasting memories by developing and selling products that solve problems in workshops, factories and homes around the world. The Company markets a wide range of maintenance products and homecare and cleaning products under the following well-known brands: WD-40®, 3-IN-ONE®, GT85®, X-14®, 2000 Flushes®, Carpet Fresh®, no vac®, Spot Shot®, 1001®, Lava® and Solvol®. 

Headquartered in San Diego, WD-40 Company recorded net sales of $408.5 million in fiscal year 2020 and its products are currently available in more than 176 countries and territories worldwide. WD-40 Company is traded on the NASDAQ Global Select market under the ticker symbol “WDFC.” For additional information about WD-40 Company please visit http://www.wd40company.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/wd-40-company-increases-quarterly-dividend-and-schedules-second-quarter-2021-earnings-conference-call-301248521.html

SOURCE WD-40 Company

MINNEAPOLIS, March 16, 2021 /PRNewswire/ — Mill City Ventures III, Ltd. (“Mill City”) (OTCQB: MCVT) announced today its participation in a purchase of two settled insurance claims. Mill City’s portion of participation was approximately $1.3M.

Mill City Chief Executive Officer Douglas M. Polinsky said, “The new year has continued to bring new funding opportunities within the scope of our core funding programs. Again, we are able to provide a valuable service in allowing people due money on adjudicated settlements to wait no longer than necessary for their money.”

“Additionally, the returns we can realize for our shareholders is significantly above risk-adjusted returns.”

Mill City’s forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements, including without limitation continued demand for short-term specialty non-bank loans, increased levels of competition, new products or offerings introduced by competitors, changes in the general economy, changes in interest rates or the market for loans, and other risks.

About Mill City Ventures III, Ltd.
Founded in 2007, Mill City Ventures III, Ltd., is a specialty finance company providing short-term non-bank lending. Additional information can be found at www.sec.gov.

View original content:http://www.prnewswire.com/news-releases/mill-city-completes-two-additional-insurance-settlement-fundings-301248518.html

SOURCE Mill City Ventures III, Ltd.

MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31^st Annual Healthcare Conference taking place virtually March 16-18, 2021.

Management is scheduled to present at 3:10pm ET on Wednesday, March 17.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.  

Media Contacts:

At Armata:

Steve Martin

Armata Pharmaceuticals, Inc.
[email protected]
858-800-2492

Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC
[email protected]
212-915-2569

View original content to download multimedia:http://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301248516.html

SOURCE Armata Pharmaceuticals, Inc.

BENSALEM, Pa., March 16, 2021 /PRNewswire/ — Law Offices of Howard G. Smith reminds investors of the upcoming April 19, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Jianpu Technology, Inc. (“Jianpu” or the “Company”) (NYSE: JT) American Depositary Shares (“ADSs” or “shares”) between May 29, 2018 and February 16, 2021, inclusive (the “Class Period”).

Investors suffering losses on their Jianpu investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

On February 16, 2021, Jianpu announced the results of its review into “transactions carried out by the Credit Card Recommendation Business Unit” with third-party business entities. The Company concluded that previously reported revenue and associated expenses had been inflated due to “certain transactions [that] involved third-party agents (including both upstream agents and downstream suppliers) with undisclosed relationships and some transactions [that] lacked business substance.” Jianpu stated that it “anticipates the total amount of overstated revenue for the fiscal years 2018 and 2019 to be approximately, RMB 90 million and RMB 164 million, respectively, representing approximately 4.5% and 10.1% of the total revenue previously reported.”

On this news, the Company’s share price fell $0.60, or 13%, to close at $3.94 per share on February 16, 2021, on unusually heavy trading volume.

If you purchased or otherwise acquired Jianpu ADSs during the Class Period, you may move the Court no later than April 19, 2021to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

View original content:http://www.prnewswire.com/news-releases/deadline-reminder-law-offices-of-howard-g-smith-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-jianpu-technology-inc-jt-301248499.html

SOURCE Law Offices of Howard G. Smith

LOS ANGELES, March 16, 2021 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 30, 2021deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”).

If you suffered a loss on your Aquestive investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/aquestive-therapeutics-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Aquestive is a specialty pharmaceutical company. Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.

On December 2, 2019, Aquestive announced the completion of the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for Libervant Buccal Film for the management of seizure clusters.

On September 25, 2020, Aquestive announced receipt of a Complete Response Letter (“CRL”) from the FDA stating that the NDA would not be approved in its current form. According to the CRL, “in a study submitted by the Company with the NDA, certain weight groups showed a lower drug exposure level than desired.” The Company stated that it “intends to provide to the FDA additional information on PK modeling to demonstrate that dose adjustments will obtain the desired exposure levels.”

On this news, Aquestive’s stock price fell $2.64 per share, or approximately 35%, to close at $4.97 per share on September 28, 2020.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data included in the Libervant NDA submission showed a lower drug exposure level than desired for certain weight groups; (2) the foregoing significantly decreased the Libervant NDA’s approval prospects; (3) as a result, it was foreseeable that the FDA would not approve the Libervant NDA in its current form; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Aquestive securities during the Class Period, you may move the Court no later than April 30, 2021to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View original content:http://www.prnewswire.com/news-releases/glancy-prongay–murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-aquestive-therapeutics-inc-aqst-301248491.html

SOURCE Glancy Prongay & Murray LLP

SHANGHAI, March 16, 2021 /PRNewswire/ — This week at SEMICON China, Advanced Micro-Fabrication Equipment Inc. China (AMEC) formally announced the Primo Twin-Star® system (Twin-Star) – a new addition to the company’s inductively coupled plasma (ICP) etch product family for FEOL and BEOL conductive/dielectric film etch applications for IC devices. 

Leveraging AMEC’s proven single-station ICP etch technology and the dual-station Primo platform, the system provides a cost-effective solution for addressing the increasingly challenging etch applications, including FEOL/BEOL dielectric and poly etch, DTI and BSI etch and etc.. Key differentiations include dual-station chamber design with minimized pumping port effect by innovative chamber design, low-capacitive coupling 3D coil design, and temperature-controlled multi-zone electrostatic chuck (ESC) that enhances CD control. With these and other unique features, the system delivers superior process performance for etching Si with various CD and depths for power device and CIS, and thin conductive/dielectric films for various logic and DRAM ICs with smaller footprint and higher productivity at a significantly lower cost of ownership (CoO) than comparative tools. As the Twin-Star system employs the same or similar design as AMEC’s single-station ICP etcher Primo nanova®, it demonstrates similar etch results in various etch applications, which delivers a cost-effective solution with superior performance and high productivity.

AMEC has received orders for the Twin-Star system from leading customers in China. Products have been shipped and the first tool is already in production and demonstrating very stable yield. More demos are requested for various etch applications. The system strengthens AMEC’s portfolio of etch tools which includes multi-generation inductively coupled plasma (ICP) dielectric etch product families.

“In this increasingly cost-sensitive manufacturing environment, our goal is to provide customers with most enabling ICP etch solution with a combination of technology innovation, high productivity and capital efficiency.” said Dr. Tom Ni, Group VP and GM of AMEC’s Etch Product and Business Group. “The Twin-Star system has demonstrated superior performance in various FEOL/BEOL applications, DTI in power device and CIS device. By providing these capabilities and a cost-effective solution, we allow our customers to solve technical challenges and meanwhile maximize the value of their capital investments.”

Primo Twin-Star is a trademark of Advanced Micro-Fabrication Equipment Inc. China.

Advanced Micro-Fabrication Equipment Inc. China (AMEC)

AMEC is China’s leading provider of process technologies, tools and expertise that help global manufacturers of semiconductors and LEDs achieve their innovation, production and profit goals. The company’s etch tools enable chipmakers to build devices for diverse applications at nodes as low as 5nm, while its MOCVD systems lead the market for the production of Blue LEDs. More than 1700 AMEC process units, comprising both product lines, have been installed at over 70 leading customer fabs across Asia and Europe. AMEC is headquartered in Shanghai with operations in Nanchang and Xiamen, and regional subsidiaries in Taiwan, Singapore, Japan, South Korea and the United States.

To learn more about AMEC, please visit www.amec-inc.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/amec-introduces-the-primo-twin-star-system–companys-dual-station-icp-etch-product-for-chipmakers-most-advanced-logic-and-dram-devices-301247752.html

SOURCE Advanced Micro-Fabrication Equipment Corp.

WASHINGTON, March 16, 2021 /PRNewswire/ — Fannie Mae (OTCQB: FNMA) announced today that it is offering Sponsor-Initiated Affordability (SIA) incentives for multifamily borrowers through its network of Delegated Underwriting and Servicing (DUS^®) lenders to lead the market in addressing the nation’s shortage of affordable multifamily housing. The incentives aim to preserve naturally occurring affordable housing (NOAH) and workforce housing by encouraging property owners seeking Fannie Mae financing to agree to rent and income restrictions for residents living in conventional workforce housing.

The SIA incentives, in the form of lower borrowing costs, will be offered to borrowers who agree to preserve or create a minimum of 20% of units in a multifamily property affordable to residents earning less than 80% percent of area median income (AMI), adjusted for family size, over the life of a loan with rents not exceeding 30% of AMI. The rent and income restrictions will be documented in an affordability agreement and will require annual certification.

“Sponsor-Initiated Affordability pricing incentives help address the shortage of affordable rental housing in America at a time when rent growth is outpacing wages. Nearly half of the families and individuals renting their home spend more than 30% of their income on rent and this share continues to rise,” said Rob Levin, Senior Vice President of Multifamily Customer Engagement, Fannie Mae. “SIA allows borrowers to strengthen communities by keeping rents affordable over the life of the loan, and helps ensure renters have more stability when it comes to housing-related expenses.”

With SIA, Fannie Mae is creating new investment opportunities to attract investors interested in social impact. The securities backed by a SIA loan will be disclosed as Multifamily Affordable Housing (MAH) mortgage-backed securities (MBS), eligible to be labeled a “social” bond, and when coupled with green financing, a “sustainable” bond.

Fannie Mae provided $76 billion in financing to support the multifamily market in 2020, the highest volume in the history of its 32-year-old DUS program, and Multifamily Affordable Housing volume rose more than 9% to $7.8 billion from $7.2 billion in 2019.

About Fannie Mae
Fannie Mae helps make the 30-year fixed-rate mortgage and affordable rental housing possible for millions of people in America. We partner with lenders to create housing opportunities for families across the country. We are driving positive changes in housing finance to make the home buying process easier, while reducing costs and risk. To learn more, visit:
fanniemae.com | Twitter | Facebook | LinkedIn | Instagram | YouTube | Blog

Fannie Mae Newsroom

https://www.fanniemae.com/news

Photo of Fannie Mae

https://www.fanniemae.com/resources/img/about-fm/fm-building.tif

Fannie Mae Resource Center
1-800-2FANNIE (800-232-6643)

View original content:http://www.prnewswire.com/news-releases/fannie-mae-introduces-sponsor-initiated-affordability-incentives-for-multifamily-borrowers-301248509.html

SOURCE Fannie Mae

CHARLES TOWN, W.Va., March 16, 2021 /PRNewswire/ — American Public Education, Inc. (NASDAQ: APEI) – parent company of online learning provider American Public University System (APUS) and on-ground pre-licensure Hondros College of Nursing – announced that Angela Selden, Chief Executive Officer, and Rick Sunderland, Executive Vice President and Chief Financial Officer, will participate in the Sidoti & Company Spring Conference on Wednesday, March 24, 2021.

Sidoti Spring 2021 Virtual Conference:

• Angela Selden will make a presentation to the financial community at 3:15 p.m. ET on Wednesday, March 24, 2021.
• A live broadcast of the presentation will be available by using this link.
• APEI management will also host one-on-one meetings with investors throughout the day. For more information about this virtual event or to schedule a meeting with management, please contact Sidoti & Company via [email protected].  

A live broadcast of the presentation will also be provided through the Events and Presentations section of APEI’s website, www.apei.com. An archive of the webcast will be available on APEI’s website for 90 days following the event.

About American Public Education


American Public Education, Inc

. (Nasdaq: APEI) is a leading provider of higher learning dedicated to preparing students all over the world for excellence in service, leadership and achievement. APEI offers respected, innovative and affordable academic programs and services to students, universities and partner organizations through wholly owned subsidiaries: American Public University System and National Education Seminars Inc., which we refer to in this press release as Hondros College of Nursing. Together, these institutions serve more than 90,000 adult learners worldwide and offer more than 240 degree and certificate programs in fields ranging from homeland security, military studies, intelligence, and criminal justice to technology, business administration, public health, nursing and liberal arts. For additional information, please visit www.apei.com.

Contact:

Chris Symanoskie, IRC
American Public Education, Inc.
Vice President, Investor Relations
703-334-3880 | [email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/american-public-education-to-participate-in-the-sidoti–company-spring-2021-virtual-conference-301248479.html

SOURCE American Public Education, Inc.